4-bromophenyl(1-propyl)sulfane | 76542-19-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-bromophenyl(1-propyl)sulfane
• 英文别名: (4-bromo-phenyl)-propyl sulfide；(4-Brom-phenyl)-propyl-sulfid；1-bromo-4-propyIsulfanyl-benzene；1-bromo-4-propylsulfanyl-benzene；(4-bromophenyl)(propyl)sulfane；1-bromo-4-(propylthio)benzene；1-Bromo-4-propylsulfanylbenzene
• CAS: 76542-19-3
• 化学式: C₉H₁₁BrS
• 分子量: 231.156
• InChiKey: XLTBVGAEUXNUNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2930909090
• 包装等级：
  III
• 危险类别：
  9
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340+P312,P305+P351+P338+P310,P332+P313,P403+P233,P405,P501
• 危险品运输编号：
  3335
• 危险性描述：
  H315,H318,H335

反应信息

• 作为反应物：
  描述：

  4-bromophenyl(1-propyl)sulfane 在 Oxone 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 1-溴-4-(丙烷-1-磺酰基)苯
  参考文献：
  名称：

  [EN] OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
  [FR] DERIVES D'OXAZOLE EN TANT QU'AGENTS DE RECEPTEUR D'HISTAMINE H3, PREPARATION ET UTILISATIONS THERAPEUTIQUES

  摘要：

  本发明公开了具有组分I（I）的新型芳基噁唑化合物或其药学上可接受的盐，其具有组胺H3受体拮抗剂或逆向激动剂活性，以及制备和使用这些化合物的方法。在另一实施方案中，本发明公开了包括组分I化合物的药物组合物，以及使用这些组合物治疗肥胖、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。组分I（I）或其药学上可接受的盐，其中：m在每次出现时独立地为1、2或3，Z独立地表示碳（用氢或此处指示的可选取代基团取代）或氮，但当Z为氮时，R6不连接到Z；R1和R2独立地为-(C1-C7)烷基（可选地用一到三个卤素取代），或者R1和R2以及它们连接的氮形成氮杂环戊二烷环、吡咯环或哌啶环，进一步地，所形成的氮杂环戊二烷、吡咯环或哌啶环可以用R5取代一到三次；R6在每次出现时独立地为-H、-卤素或-CH3。

  公开号：

  WO2006019833A1
• 作为产物：
  描述：

  1-碘代丙烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 4-bromophenyl(1-propyl)sulfane
  参考文献：
  名称：

  [EN] OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
  [FR] DERIVES D'OXAZOLE EN TANT QU'AGENTS DE RECEPTEUR D'HISTAMINE H3, PREPARATION ET UTILISATIONS THERAPEUTIQUES

  摘要：

  本发明公开了具有组分I（I）的新型芳基噁唑化合物或其药学上可接受的盐，其具有组胺H3受体拮抗剂或逆向激动剂活性，以及制备和使用这些化合物的方法。在另一实施方案中，本发明公开了包括组分I化合物的药物组合物，以及使用这些组合物治疗肥胖、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。组分I（I）或其药学上可接受的盐，其中：m在每次出现时独立地为1、2或3，Z独立地表示碳（用氢或此处指示的可选取代基团取代）或氮，但当Z为氮时，R6不连接到Z；R1和R2独立地为-(C1-C7)烷基（可选地用一到三个卤素取代），或者R1和R2以及它们连接的氮形成氮杂环戊二烷环、吡咯环或哌啶环，进一步地，所形成的氮杂环戊二烷、吡咯环或哌啶环可以用R5取代一到三次；R6在每次出现时独立地为-H、-卤素或-CH3。

  公开号：

  WO2006019833A1

文献信息

• PROCESS FOR THE REMOVAL AND RETURN OF A CATALYST TO A LIQUID PHASE MEDIUM
  申请人：PHOSPHONICS LTD

  公开号：US20150299229A1

  公开（公告）日：2015-10-22

  A process for the selective removal of a component from a liquid phase and subsequently returning the component to a liquid phase is disclosed. A novel compound of formula (I) [SUP]-[[L]-[G]]a (I) in which L is a linking group, G is an aryl group having a leaving group LG selected from Cl, Br, I, sulfonate such as triflate, a diazo group, a nitrile, an ester and an alkoxy group and substituent Q is selected from H, NR2, OR, C02R, F, Cl, N02 CN and SUP is a support having a plurality of groups -[L]-[G] bound to the support is contacted with the liquid phase to bind the component to the compound I thereby forming a captured component which is separated from and may be returned to the liquid phase. The compound I is especially useful in binding homogeneous catalysts to remove it from a reaction medium and selectively returning the catalyst to the reaction medium at a later stage. The compound is particularly useful for cross-coupling reactions, for example in Suzuki reactions.

  揭示了一种从液相中选择性去除组分并随后将该组分返回到液相的方法。公开了一种具有式(I)的新化合物[SUP]-[[L]-[G]]a (I)，其中L是连接基团，G是一种芳基团，具有从Cl、Br、I、磺酸盐（如三氟甲磺酸盐）、重氮基团、腈基、酯基和烷氧基中选择的离去基团LG，取代基Q从H、NR2、OR、C02R、F、Cl、N02、CN中选择，SUP是具有多个与支持物相结合的基团-[L]-[G]的支持物，与液相接触以将组分结合到化合物I中，从而形成被捕获的组分，该组分与液相分离并可以返回到液相中。化合物I在将均相催化剂结合以将其从反应介质中去除，并在后续阶段选择性地将催化剂返回到反应介质中方面特别有用。该化合物特别适用于交叉偶联反应，例如在铃木反应中。
• [EN] SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP<br/>[FR] MODULATEURS SELECTIFS DES RECEPTEURS OESTROGENIQUES CONTENANT UN GROUPE PHENYLSULFONYLE
  申请人：LILLY CO ELI

  公开号：WO2004009086A1

  公开（公告）日：2004-01-29

  The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

  本发明涉及式I的选择性雌激素受体调节剂或其药用酸盐加合物；例如，用于治疗子宫内膜异位症和/或子宫平滑肌瘤。
• New series of thio-derivatives of basic benzhydryl ethers and thioethers
  申请人：HERMAN HUBNER OLUF

  公开号：US02830088A1

  公开（公告）日：1958-04-08

  The invention comprises thio- or sulphonyl-substituted basic benzhydryl ethers and thioethers having sedative properties and represented by the formula wherein R is hydrogen, chlorine, bromine or iodine; R1 and R2 are alkylsulphonyl, alkylmercapto, phenyl- or substituted phenylmercapto, cycloalkyl- or substituted cycloalkylmercapto or hydrogen, and may be the same except when one of them is hydrogen; Z is oxygen or sulphur; and X is dialkylaminoalkyl, morpholinyl-substituted alkyl, piperidyl-substituted alkyl or N-alkyl-substituted C-piperidyl; and their acid or quaternary ammonium salts. They may be prepared by reacting a benzhydryl halide of the formula with the appropriate amino-alcohol or amino-thio-alcohol or their alkali metal salts; or by reacting the amino-halide with an appropriately substituted benzhydrol or benzhydryl-thio-alcohol or an alkali metal salt thereof. Solvents may be present. Examples disclose the preparation of hydrochlorides or citrates of the following compounds: benzhydryl 2-dimethylaminoethyl sulphides in which the benzhydryl group is substituted by p-methyl, p-ethyl, p-isopropyl-, o-, m- and p-butyl-, m- and p-hexyl-, p-cyclohexyl-, p-octyl- and p-phenyl-mercapto groups and by p,p1-bis(n-hexyl-, propyl- and butyl-mercapto) groups and by p-butyl sulphonyl: the p-butyl- and m-bromo-p1-butylmercapto and p,p1-bis(butylmercapto)-benzyhydryl 2-diethyl aminoethyl sulphides: m- and p-butyl-mercapto-benzhydryl 2-dimethylaminoethyl ethers: p-butylmercaptobenzhydryl-4-dimethyl-aminobutyl ether: p-butylmercaptobenzhydryl 2-(4-morpholinyl) ethyl ether and sulphide; p-butyl mercaptobenzhydryl 2-dimethylaminopropyl ether and sulphide: p-butylmercaptobenzhydryl 4-(1-methyl)-piperidyl sulphide: p-methylmercaptobenzhydryl 2-(1 - piperidyl) - ethyl ether: p-hexylmercaptobenzhydryl 2-(4-morpholinyl)-ethyl sulphide. The p-alkylmercaptobenzhydryl chlorides, used as starting materials, are prepared by reducing the p-alkyl mercaptobenzophenones (obtained from the p-alkylphenyl sulphides) with zinc and sodium hydroxide to the alcohol and then saturating with anhydrous HCl. The p-phenylmercapto-derivative is similarly prepared. The m-alkyl mercaptobenzhydryl chlorides are similarly prepared from the m-alkylmercaptobenzophenones which are obtained from the m-alkylmercaptobenzoyl chloride, benzene and anhydrous AlCl3 in CS2. The alkylmercaptobenzhydryl mercaptans are prepared by boiling the chloride with thiourea yielding the alkylmercaptobenzhydrylisothiouronium chloride which is then hydrolysed with aqueous sodium hydroxide. p-Butyl sulphonylbenzophenone is obtained by oxidizing p-butyl mercaptobenzophenone with hydrogen peroxide in glacial acetic acid. m - Bromo - p1 - butylmercaptobenzhydryl chloride is prepared by reacting butyl phenyl sulphide with m-bromobenzoyl chloride by the Friedel-Crafts synthesis to yield m-bromo-p1-butylmercaptobenzophenone, which is reduced by zinc and KOH to the alcohol which is then treated with HCl. p - Bromophenyl - n - butyl sulphide, prepared by brominating p-n-butyl phenyl sulphide, is converted to p-butyl mercaptobenzoic acid by carbonation of a Grignard derivative with CO2. The acid chloride, obtained by treatment with thionyl chloride, is reacted with butyl phenyl sulphide as above, yielding p,p1-bis (butylmercapto)-benzophenone. This is reduced to give p,p1-bis(butylmercapto)-benzhydrol, which is treated with HCl to give the chloride. Similar methods produce the p,p1-bis(propyl-and hexyl-mercapto)-derivatives.

  这项发明包括具有镇静性能的硫代或磺代基本苯基二苯基醚和硫醚，其化学式表示为，其中R为氢、氯、溴或碘；R1和R2为烷基磺酰基、烷基硫醇基、苯基或取代苯基硫醇基、环烷基或取代环烷基硫醇基或氢，除非其中一个是氢；Z为氧或硫；X为二烷胺基烷基、吗啉基取代烷基、哌啶基取代烷基或N-烷基取代C-哌啶基；以及它们的酸或季铵盐。它们可以通过将化学式的二苯基卤化物与适当的氨基醇或氨基硫醇或它们的碱金属盐反应来制备；或者通过将氨基卤化物与适当取代的苯基醇或苯基硫醇醇或其碱金属盐反应来制备。溶剂可以存在。示例揭示了以下化合物的盐酸盐或柠檬酸盐的制备：苯基二甲基氨基乙基硫化物，其中苯基基被p-甲基、p-乙基、p-异丙基、o-、m-和p-丁基、m-和p-己基、p-环己基、p-辛基和p-苯基硫醇基取代，以及p,p1-双(n-己基、丙基和丁基硫醇基)基和p-丁基磺酰基取代；p-丁基和m-溴-p1-丁基硫醇基和p,p1-双(丁基硫醇基)-苯基二乙基氨基乙基硫化物；m-和p-丁基硫醇基苯基二甲基氨基乙基醚；p-丁基硫醇基苯基二(4-吗啉基)乙基醚和硫化物；p-丁基硫醇基苯基二甲基氨基丙基醚和硫化物；p-丁基硫醇基苯基四(1-甲基)-哌啶基硫化物；p-甲基硫醇基苯基二(1-哌啶基)-乙基醚；p-己基硫醇基苯基二(4-吗啉基)-乙基硫化物。作为起始原料使用的p-烷基硫醇基苯基氯化物是通过将p-烷基硫醇基苯酮（从p-烷基苯基硫醇基获得）与锌和氢氧化钠还原为醇，然后用无水HCl饱和得到的。p-苯基硫醇基衍生物类似制备。m-烷基硫醇基苯基氯化物类似地从m-烷基硫醇基苯酮制备，后者是通过m-烷基硫醇基苯酰氯、苯和无水AlCl3在CS2中反应获得的。烷基硫醇基苯基硫醇基硫醇通过将氯化物与硫脲沸腾制备，得到的烷基硫醇基苯基硫醇基硫脲盐随后与水合氢氧化钠水解。p-丁基磺酰基苯酮是通过在冰乙酸中用过氧化氢氧化p-丁基硫醇基苯酮得到的。m-溴-p1-丁基硫醇基苯基氯化物是通过将丁基苯硫化物与m-溴苯甲酰氯在Friedel-Crafts合成中反应得到m-溴-p1-丁基硫醇基苯酮，然后通过锌和KOH还原为醇，再用HCl处理得到。由溴化p-正丁基苯硫化物制备的p-溴苯基-n-正丁硫醚通过用CO2与格氏试剂衍生物碳化得到p-丁基硫醇基苯甲酸。酸氯化物通过与氯化硫酰反应得到，然后与p-正丁基苯硫化物反应，得到p,p1-双(正丁硫醇基)-苯酮。这经还原得到p,p1-双(正丁硫醇基)-苯醇，再经HCl处理得到氯化物。类似方法可制备p,p1-双(丙基和己基硫醇基)-衍生物。
• Enantioselective Nitrene Transfer to Sulfides Catalyzed by a Chiral Iron Complex
  作者：Jun Wang、Marcus Frings、Carsten Bolm

  DOI：10.1002/anie.201304451

  日期：2013.8.12

  Iron works: Enantioselective nitrene transfer to sulfide was accomplished by a chiral iron(III)/PyBOX catalyst (see scheme). Various sulfimides were thus obtained in high enantioselectivities and yields. Applications of this protocol to the syntheses of enantioenriched sulfoximines and an epoxide were also demonstrated.

  铁厂：通过手性铁（III）/ PyBOX催化剂（参见方案）可实现对映选择性的腈转化为硫化物。因此以高对映选择性和产率获得了各种磺酰亚胺。还证明了该方案在对映体富集的亚砜亚胺和环氧化物的合成中的应用。
• [EN] 2-AZA-BICYCLO[2.2.2]OCTANE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS 2-AZA-BICYCLO[2.2.2]OCTANE ET LEURS UTILISATIONS
  申请人：ASTRAZENECA AB

  公开号：WO2010087761A1

  公开（公告）日：2010-08-05

  This invention relates to 2-aza-bicyclo [2.2.2] octane compounds (and salts thereof), the process for making such a compound and pharmaceutical compositions comprising such a compound. The invention also relates to the use of the compounds for modulating the glycine transporter 1 (GIyTl) and for the treatment of psychosis, cognitive disorders, bipolar disorders, depression disorders, anxiety disorders, posttraumatic stress disorders and pain.

  这项发明涉及2-aza-bicyclo [2.2.2]辛烷化合物（及其盐），制备这种化合物的过程以及包含这种化合物的药物组合物。该发明还涉及利用这些化合物调节甘氨酸转运蛋白1（GIyTl）并用于治疗精神病、认知障碍、双相情感障碍、抑郁症、焦虑症、创伤后应激障碍和疼痛。